Xlife Sciences plans NASDAQ IPO for VERAXA Biotech in 2025
Xlife Sciences announces planned NASDAQ listing of VERAXA Biotech in 2025, focusing on next-gen antibody-drug candidates and bispecific T-cell engagers for cancer treatment.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.